MMedication Read More Can Wegovy Pill’s Rapid Uptake Give Novo Nordisk an Edge Over LLY?June 8, 2026 Novo Nordisk NVO remains one of the dominant players in the rapidly expanding obesity treatment market. The company markets…
HHealthcare Read More Eli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 SuccessJune 6, 2026 The pharmaceutical industry is highly technical and incredibly competitive. That is on clear display right now in the…
MMedication Read More Why Canadians can now get cheaper generic OzempicJune 5, 2026 Elizabeth Doran has been taking GLP-1 medications for nearly a year for weight loss to help reverse her…
MMedication Read More Weight Loss Drugs Listed By Health Insurers Aren’t Necessarily CoveredJune 2, 2026 Eli Lilly’s Foundayo weight loss oral pill competes against Novo Nordisk’s oral Wegovy. (Photo by: Michael Siluk/UCG/Universal Images…
MMedication Read More Brazil approves first generic semaglutide pen after Ozempic patent expiryMay 26, 2026 SAO PAULO, May 26 (Reuters) – Brazil’s health regulator Anvisa said on Tuesday it had approved EMS’s Ozivy,…
MMedication Read More How GLP-1s are more than just weight-loss wonders – but not without riskMay 23, 2026 Not long ago, nobody was talking about GLP-1 receptor agonists. Most of us did not even know what…
MMedication Read More LLY Stock: Foundayo Data Bolsters Weight-Loss Maintenance CaseMay 22, 2026 Shares of Eli Lilly and Company NYSE: LLY, the world’s most valuable pharmaceutical stock, started 2026 in a…
MMedication Read More Lower cost Novo, Lilly weight-loss pills draw patients from compounded drugs, doctors sayMay 21, 2026 By Bhanvi Satija and Chris Prentice LONDON/NEW YORK, May 21 (Reuters) – Lower prices for weight-loss pills from…
MMedication Read More Could Eli Lilly’s Next Weight Loss Drug Waylay Wegovy — and Even Zap Zepbound?May 17, 2026 After losing its market edge to Eli Lilly (NYSE: LLY) despite its first-mover advantage in weight-loss drugs, Novo…
HHealthcare Read More Best Healthcare Stocks to Buy in 2026May 15, 2026 Biogen (NASDAQ: BIIB) and Novo Nordisk (NYSE: NVO) represent different opportunities within the healthcare sector: One is a…
MMedication Read More Novo Nordisk’s high-dose Wegovy touts near 28% weight loss in early respondersMay 13, 2026 Novo Nordisk has shared new data that suggests a higher dose version of its blockbuster weight loss drug,…
MMedication Read More Oral Ozempic US Launch And Partnerships Test Novo Nordisk ValuationMay 8, 2026 Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…